This strategy holds true not only for BRCA‐1/2 deficient tumours, but hypoxic cancer cells demonstrate defective HR pathways, such as TNBC cells, which can be therapeutically exploited to induce greater radiosensitization.54, 55. The gene discussed is BRCA1; the disease is neoplasm.